Landos Biopharma, Inc. (LABP) Stock Analysis
DELISTED 2024
What happened to Landos Biopharma, Inc. (LABP) stock?
Landos Biopharma, Inc. (LABP) no longer trades on public markets. It was delisted in May 2024. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- May 2024
- Last recorded price (historical):
- $22.93 (last quote on record before the May 2024 delisting; historical, not a current quote)
Market cap $71.7M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Landos Biopharma, Inc. (LABP). Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for autoimmune diseases. Their lead product candidate, omilancor, targets ulcerative colitis, Crohn's disease, and eosinophilic esophagitis.
Last analyzed: Mar 16, 2026Landos Biopharma, Inc. (LABP) Healthcare & Pipeline Overview
More about this archive record
Can I still buy LABP shares?
No. LABP stopped trading on public markets in May 2024, so the shares are not available through a broker. Anything you see quoted for LABP elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before LABP stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Landos Biopharma, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.